Live Breaking News & Updates on அடித்தளம் ஆராய்ச்சி மையம்|Page 2

Stay updated with breaking news from அடித்தளம் ஆராய்ச்சி மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market


Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market
MELBOURNE, Australia (BUSINESS WIRE)
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Proenzymes Optimization Project 1 (“POP1”) joint research and drug discovery program advanced towards producing commercial scale quantities of the two proenzymes trypsinogen and chymotrypsinogen. The Company’s product candidate is targeting the global metastatic cancer treatment market, projected to be worth US$111.2 Billion by 2027, according to current analysis by Emergen Research. ....

Spain General , Aitor Gonz , James Nathanielsz , Julian Kenyon , Profit Research Organization , University Of Granada , Company Registration Statement On Form , Company Mechanism Of Action , Exchange Commission , Emergen Research , Foundation Research Center , Propanc Biopharma Inc , Propanc Biopharma , Proenzymes Optimization Project , Research Center , Non Profit Research Organization , Regional Government , Merck Sharp , Dohme De Espa , Natural Product Chemistry , Macarena Per , Chief Scientific Officer , Chief Executive Officer , Registration Statement , ஸ்பெயின் ஜநரல் , ஜூலியன் கெந்யந் ,